Klaus Pantel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/352372/publications.pdf

Version: 2024-02-01

314	45,578	2963	1974
papers	citations	93 h-index	206 g-index

320	320	320	41440
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metabolic regulation of prostate cancer heterogeneity and plasticity. Seminars in Cancer Biology, 2022, 82, 94-119.	4.3	20
2	Possible tumour cell reimplantation during curative endoscopic therapy of superficial Barrettâ€™s carcinoma. Gut, 2022, 71, 277-286.	6.1	4
3	Clinical management and biology of tumor dormancy in breast cancer. Seminars in Cancer Biology, 2022, 78, 49-62.	4.3	24
4	Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer. Clinical Chemistry, 2022, 68, 344-353.	1.5	5
5	Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. Clinical and Experimental Metastasis, 2022, 39, 159-179.	1.7	30
6	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. Cancer Research, 2022, 82, 349-358.	0.4	57
7	Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treatment Reviews, 2022, 102, 102322.	3.4	29
8	Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors inÂvivo. Molecular Therapy, 2022, 30, 1536-1552.	3.7	6
9	Metastatic Breast Cancer Recurrence after Bone Fractures. Cancers, 2022, 14, 601.	1.7	3
10	Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. Cancers, 2022, 14, 635.	1.7	6
11	Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells. Cancers, 2022, 14, 556.	1.7	2
12	Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. Journal of Experimental and Clinical Cancer Research, 2022, 41, 46.	3.5	43
13	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. Oncologist, 2022, 27, e561-e570.	1.9	5
14	Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses. Molecular Cancer, 2022, 21, 73.	7.9	16
15	Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. Npj Precision Oncology, 2022, 6, 17.	2.3	7
16	Circulating Tumor-Macrophage Fusion Cells and Circulating Tumor Cells Complement Nonâ€“Small-Cell Lung Cancer Screening in Patients With Suspicious Lung-RADS 4 Nodules. JCO Precision Oncology, 2022, 6, e2100378.	1.5	5
17	Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer. Clinical Chemistry, 2022, 68, 973-983.	1.5	2
18	Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. British Journal of Cancer, 2022, 127, 800-810.	2.9	38

#	Article	IF	Citations
19	Detection and Characterization of Estrogen Receptor Î± Expression of Circulating Tumor Cells as a Prognostic Marker. Cancers, 2022, 14, 2621.	1.7	3
20	Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions. British Journal of Cancer, 2022, 127, 1403-1410.	2.9	13
21	Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients. Cancer Research, 2022, 82, 3374-3374.	0.4	1
22	Circulating DNA and Liquid Biopsies in the Management of Patients with Cancer. Cancer Research, 2022, 82, 2213-2215.	0.4	11
23	Heparan sulfate dependent binding of plasmatic von Willebrand factor to blood circulating melanoma cells attenuates metastasis. Matrix Biology, 2022, 111, 76-94.	1.5	3
24	Liquid biopsies: Potential and challenges. International Journal of Cancer, 2021, 148, 528-545.	2.3	146
25	Sensitive Blood-Based Detection of Asbestos-Associated Diseases Using Cysteine-Rich Angiogenic Inducer 61 as Circulating Protein Biomarker. Clinical Chemistry, 2021, 67, 363-373.	1.5	3
26	Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. British Journal of Cancer, 2021, 124, 345-358.	2.9	238
27	Prospective Comparison of the Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of a Single Patient's Cohort With Esophageal Cancer. Annals of Surgery, 2021, 273, 299-305.	2.1	21
28	Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. Clinical Chemistry, 2021, 67, 631-641.	1.5	25
29	Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells. Cancers, 2021, 13, 563.	1.7	6
30	Liquid Biopsy: From Discovery to Clinical Application. Cancer Discovery, 2021, 11, 858-873.	7.7	407
31	Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2â^' Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2â^' Breast Cancer. Cancers, 2021, 13, 1810.	1.7	13
32	Novel approaches to target the microenvironment of bone metastasis. Nature Reviews Clinical Oncology, 2021, 18, 488-505.	12.5	91
33	Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. Biochemical Pharmacology, 2021, 188, 114589.	2.0	18
34	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. International Journal of Molecular Sciences, 2021, 22, 6993.	1.8	26
35	Liquid biopsy: from discovery to clinical implementation. Molecular Oncology, 2021, 15, 1617-1621.	2.1	9
36	Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer. PLoS ONE, 2021, 16, e0252897.	1.1	17

#	Article	IF	Citations
37	Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer. Cancers, 2021, 13, 3869.	1.7	14
38	A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. Clinical Chemistry, 2021, 67, 1395-1405.	1.5	12
39	Liquid Biopsy: Blood-Based Analyses of ctDNA and CTCs. Clinical Chemistry, 2021, 67, 1437-1439.	1.5	3
40	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer. Cancers, 2021, 13, 4500.	1.7	11
41	Bloodâ€based detection of lung cancer using cysteineâ€rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study. Molecular Oncology, 2021, 15, 2877-2890.	2.1	5
42	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 2021, 154, 128-137.	1.3	24
43	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. Carcinogenesis, 2021, 42, 1475-1484.	1.3	5
44	Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. Neuro-Oncology, 2021, 23, 1087-1099.	0.6	59
45	Detection of Circulating Tumor Cells (CTCs) in Patients with Testicular Germ Cell Tumors. Methods in Molecular Biology, 2021, 2195, 245-261.	0.4	3
46	BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. Molecular Oncology, 2021, 15, 3615-3625.	2.1	8
47	High Serum Levels of Wnt Signaling Antagonist Dickkopf-Related Protein 1 Are Associated with Impaired Overall Survival and Recurrence in Esophageal Cancer Patients. Cancers, 2021, 13, 4980.	1.7	5
48	AXL Inhibition Represents a Novel Therapeutic Approach in Negative Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e630.	1.2	0
49	Evaluation of the Hamburg-Glasgow Classification in Pancreatic Cancer: Preoperative Staging by Combining Disseminated Tumor Load and Systemic Inflammation. Cancers, 2021, 13, 5942.	1.7	2
50	Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments. Cell Death and Disease, 2021, 12, 1118.	2.7	9
51	Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. Molecular Aspects of Medicine, 2020, 72, 100817.	2.7	49
52	Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. Clinical Chemistry, 2020, 66, 149-160.	1.5	100
53	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. Clinical Chemistry, 2020, 66, 161-168.	1.5	21
54	Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray Platform. Advanced Biology, 2020, 4, 1900162.	3.0	19

#	Article	IF	Citations
55	A New Era in Liquid Biopsy: From Genotype to Phenotype. Clinical Chemistry, 2020, 66, 89-96.	1.5	27
56	Molecular and Functional Characterization of Circulating Tumor Cells: From Discovery to Clinical Application. Clinical Chemistry, 2020, 66, 97-104.	1.5	33
57	The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis. Cell Death and Disease, 2020, 11, 873.	2.7	10
58	International liquid biopsy standardization alliance white paper. Critical Reviews in Oncology/Hematology, 2020, 156, 103112.	2.0	66
59	MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. Cancers, 2020, 12, 2009.	1.7	40
60	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. Cells, 2020, 9, 2337.	1.8	13
61	High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors. Cells, 2020, 9, 2129.	1.8	26
62	EGFR as a stable marker of prostate cancer dissemination to bones. British Journal of Cancer, 2020, 123, 1767-1774.	2.9	27
63	Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy. Scientific Reports, 2020, 10, 21562.	1.6	6
64	The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy. Journal of Clinical Medicine, 2020, 9, 3478.	1.0	5
65	Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis. Cancers, 2020, 12, 1166.	1.7	10
66	Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). OncoImmunology, 2020, 9, 1738798.	2.1	34
67	In Vitro Modeling of Reoxygenation Effects on mRNA and Protein Levels in Hypoxic Tumor Cells upon Entry into the Bloodstream. Cells, 2020, 9, 1316.	1.8	13
68	Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape. Acta Neuropathologica Communications, 2020, 8, 28.	2.4	24
69	Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer. Cancers, 2020, 12, 588.	1.7	3
70	Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method. Cancers, 2020, 12, 718.	1.7	15
71	Circulating Giant Tumor-Macrophage Fusion Cells Are Independent Prognosticators in Patients With NSCLC. Journal of Thoracic Oncology, 2020, 15, 1460-1471.	0.5	44
72	Blood tests for early detection of lung cancer: challenges and promises. Lancet Respiratory Medicine,the, 2020, 8, 654-656.	5.2	3

#	Article	IF	Citations
73	Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients. Cancers, 2020, 12, 442.	1.7	28
74	ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. Neuro-Oncology, 2020, 22, 955-966.	0.6	36
75	Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer. Cancers, 2020, 12, 160.	1.7	32
76	Molecular Diagnostics: Going from Strength to Strength. Clinical Chemistry, 2020, 66, 1-2.	1.5	2
77	Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. Cancers, 2020, 12, 1055.	1.7	19
78	Preâ€analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. Molecular Oncology, 2020, 14, 1001-1015.	2.1	19
79	The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 2161.	1.8	6
80	Pathophysiology of Tumor Cell Release into the Circulation and Characterization of CTC. Recent Results in Cancer Research, 2020, 215, 3-24.	1.8	2
81	HER2-targeted therapy influences CTC status in metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 182, 127-136.	1.1	21
82	A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 3029-3029.	0.8	6
83	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Molecular Medicine, 2020, 12, e11908.	3.3	77
84	Circulating Tumor Cells in Head and Neck Carcinomas. Clinical Chemistry, 2019, 65, 1193-1195.	1.5	6
85	In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. Cancers, 2019, 11, 933.	1.7	18
86	Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. Cancers, 2019, 11, 1685.	1.7	23
87	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nature Reviews Cancer, 2019, 19, 553-567.	12.8	393
88	Clonality of circulating tumor cells in breast cancer brain metastasis patients. Breast Cancer Research, 2019, 21, 101.	2.2	54
89	Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer. Cells, 2019, 8, 1067.	1.8	18
90	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. International Journal of Cancer, 2019, 145, 857-868.	2.3	12

#	Article	IF	Citations
91	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. Cancers, 2019, 11, 835.	1.7	109
92	Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. Cancers, 2019, 11, 802.	1.7	24
93	EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Scientific Reports, 2019, 9, 7406.	1.6	73
94	Characterization of circulating DNA in plasma of patients after allogeneic bone grafting. Clinical Oral Investigations, 2019, 23, 4243-4253.	1.4	15
95	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. Journal of Extracellular Vesicles, 2019, 8, 1588555.	5.5	86
96	Liquid biopsy and minimal residual disease â€" latest advances and implications for cure. Nature Reviews Clinical Oncology, 2019, 16, 409-424.	12.5	671
97	Interplay of lncRNA H19/miRâ€675 and lncRNA NEAT1/miRâ€204 in breast cancer. Molecular Oncology, 2019, 13, 1137-1149.	2.1	84
98	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Scientific Reports, 2019, 9, 2318.	1.6	27
99	ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer. Translational Research, 2019, 203, 49-56.	2.2	13
100	Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. Clinical Chemistry, 2019, 65, 87-99.	1.5	109
101	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 2019, 134, 39-45.	2.0	200
102	Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. Clinical Chemistry, 2019, 65, 462-472.	1.5	24
103	Liquid biopsies. Genes Chromosomes and Cancer, 2019, 58, 219-232.	1.5	117
104	Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. Journal of the National Cancer Institute, 2019, 111, 380-387.	3.0	101
105	Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer. International Journal of Cancer, 2019, 144, 607-614.	2.3	11
106	Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 173, 155-165.	1.1	11
107	Biology and clinical relevance of EpCAM. Cell Stress, 2019, 3, 165-180.	1.4	127
108	Circulating tumour cells in prostate cancer. Nature Reviews Urology, 2018, 15, 265-266.	1.9	14

#	Article	IF	Citations
109	Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. Cancer Research, 2018, 78, 3220-3232.	0.4	84
110	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 560-567.	3.0	206
111	Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells. Developmental Cell, 2018, 45, 33-52.e12.	3.1	219
112	Clinical applications of the CellSearch platform in cancer patients. Advanced Drug Delivery Reviews, 2018, 125, 102-121.	6.6	185
113	Profiling circulating tumour cells and other biomarkers of invasive cancers. Nature Biomedical Engineering, 2018, 2, 72-84.	11.6	187
114	In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells. Clinical Chemistry, 2018, 64, 536-546.	1.5	66
115	Advances in liquid biopsy approaches for early detection and monitoring of cancer. Genome Medicine, 2018, 10, 21.	3.6	85
116	BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica, 2018, 103, 939-948.	1.7	23
117	Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer. Clinical Cancer Research, 2018, 24, 2844-2850.	3.2	78
118	Disseminated breast tumour cells: biological and clinical meaning. Nature Reviews Clinical Oncology, 2018, 15, 129-131.	12.5	42
119	Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. Clinical Chemistry, 2018, 64, 297-306.	1.5	67
120	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. Scientific Reports, 2018, 8, 17535.	1.6	23
121	Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease. Cancers, 2018, 10, 527.	1.7	45
122	Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine, 2018, 16, 179.	2.3	134
123	Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. Scientific Reports, 2018, 8, 15931.	1.6	67
124	Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e243-e246.	0.5	18
125	Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Scientific Reports, 2018, 8, 12974.	1.6	59
126	Clinical utility of circulating non-coding RNAs â€" an update. Nature Reviews Clinical Oncology, 2018, 15, 541-563.	12.5	353

#	Article	IF	Citations
127	Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases. Analytical Cellular Pathology, 2018, 2018, 1-8.	0.7	8
128	Inverse Perfusion Requirements of Supra- and Infratentorial Brain Metastases Formation. Frontiers in Neurology, 2018, 9, 391.	1.1	5
129	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 172, 93-104.	1.1	28
130	Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients. Clinical Chemistry, 2018, 64, 1505-1512.	1.5	18
131	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. BMC Cancer, 2018, 18, 541.	1.1	6
132	Clinical relevance of cytoskeleton associated proteins for ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2195-2205.	1.2	35
133	Exosomal micro<scp>RNA</scp>s as tumor markers in epithelial ovarian cancer. Molecular Oncology, 2018, 12, 1935-1948.	2.1	125
134	Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization. Journal of Visualized Experiments, 2018, , .	0.2	1
135	Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases. Scientific Reports, 2018, 8, 8751.	1.6	15
136	Prevalence of circulating tumor cells in early breast cancer patients 2 and 5Âyears after adjuvant treatment. Breast Cancer Research and Treatment, 2018, 171, 571-580.	1.1	12
137	Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis. Blood, 2018, 132, 1922-1922.	0.6	3
138	Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.. Journal of Clinical Oncology, 2018, 36, 515-515.	0.8	20
139	Detection and oncological impact of circulating tumor cells in bladder cancer patients with presence of copy number variations of circulating cell free DNA.. Journal of Clinical Oncology, 2018, 36, 495-495.	0.8	1
140	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. Clinical Breast Cancer, 2017, 17, 279-285.	1.1	10
141	Catch and Release: rare cell analysis from a functionalised medical wire. Scientific Reports, 2017, 7, 43424.	1.6	17
142	Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. BJU International, 2017, 119, 854-861.	1.3	27
143	Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell, 2017, 31, 172-179.	7.7	395
144	Tumour microenvironment: informing on minimal residual disease in solid tumours. Nature Reviews Clinical Oncology, 2017, 14, 325-326.	12.5	40

#	Article	IF	Citations
145	Characterization of single circulating tumor cells. FEBS Letters, 2017, 591, 2241-2250.	1.3	48
146	Nanoplatforms for Circulating Tumor Cell Detection in Lung Cancer. Clinical Chemistry, 2017, 63, 1318-1320.	1.5	1
147	Plasma microRNA signature is associated with risk stratification in prostate cancer patients. International Journal of Cancer, 2017, 141, 1231-1239.	2.3	40
148	Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells. Advances in Experimental Medicine and Biology, 2017, 994, 205-228.	0.8	34
149	Epithelial-mesenchymal plasticity in circulating tumor cells. Journal of Molecular Medicine, 2017, 95, 133-142.	1.7	113
150	Tracing the Seeds in the Soil. Clinical Chemistry, 2017, 63, 1764-1765.	1.5	2
151	Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell, 2017, 32, 731-747.e6.	7.7	133
152	Liquid Biopsy: Current Status and Future Perspectives. Oncology Research and Treatment, 2017, 40, 404-408.	0.8	177
153	Hamburg-Glasgow classification: preoperative staging by combination of disseminated tumour load and systemic inflammation in oesophageal carcinoma. British Journal of Cancer, 2017, 117, 612-618.	2.9	6
154	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clinical Cancer Research, 2017, 23, 5384-5393.	3.2	85
155	A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. International Journal of Cancer, 2017, 140, 381-389.	2.3	33
156	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitorâ€“Sensitive and -Resistant Chronic Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 2289-2300.	3.2	38
157	Circulating and disseminated tumour cells â€" mechanisms of immune surveillance and escape. Nature Reviews Clinical Oncology, 2017, 14, 155-167.	12.5	426
158	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. Scientific Reports, 2017, 7, 17307.	1.6	16
159	Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precision Oncology, 2017, 1, 1-12.	1.5	9
160	FlÃ¼ssigbiopsie: Status quo und Zukunftsperspektiven. Karger Kompass Pneumologie, 2017, 5, 206-210.	0.0	0
161	Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget, 2017, 8, 56398-56407.	0.8	25
162	Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells. Oncotarget, 2017, 8, 56066-56080.	0.8	56

#	Article	IF	Citations
163	Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. Translational Lung Cancer Research, 2017, 6, 431-443.	1.3	25
164	PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression. Oncotarget, 2017, 8, 6155-6168.	0.8	35
165	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget, 2017, 8, 89978-89987.	0.8	58
166	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Anticancer Research, 2017, 37, 3117-3128.	0.5	14
167	Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget, 2016, 7, 16923-16935.	0.8	207
168	Diverse expression patterns of the <scp>EMT</scp> suppressor grainyheadâ€like 2 (<scp>GRHL</scp>2) in normal and tumour tissues. International Journal of Cancer, 2016, 138, 949-963.	2.3	18
169	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Scientific Reports, 2016, 6, 39736.	1.6	96
170	Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. Clinical Chemistry, 2016, 62, 1504-1515.	1.5	130
171	Genetic traits for hematogeneous tumor cell dissemination in cancer patients. Cancer and Metastasis Reviews, 2016, 35, 41-48.	2.7	20
172	Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy. Pharmacogenomics, 2016, 17, 183-186.	0.6	24
173	Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 160, 277-290.	1.1	23
174	A shocking protein complex. Nature, 2016, 538, 322-323.	13.7	5
175	Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2â€negative metastatic breast cancer. Molecular Oncology, 2016, 10, 1330-1343.	2.1	53
176	TP53 mutations on circulating cell-free DNA. EBioMedicine, 2016, 10, 15-16.	2.7	3
177	Chronic UVB-irradiation actuates perpetuated dermal matrix remodeling in female mice: Protective role of estrogen. Scientific Reports, 2016, 6, 30482.	1.6	9
178	Characterization of different CTC subpopulations in non-small cell lung cancer. Scientific Reports, 2016, 6, 28010.	1.6	91
179	Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. Advances in Experimental Medicine and Biology, 2016, 924, 3-8.	0.8	37
180	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. Clinical Chemistry, 2016, 62, 1054-1060.	1.5	87

#	Article	IF	Citations
181	Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. European Journal of Cancer, 2016, 63, 97-104.	1.3	44
182	Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Research, 2016, 18, 8.	2.2	226
183	Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells. Clinical Cancer Research, 2016, 22, 2197-2206.	3.2	135
184	Functional Studies on Viable Circulating Tumor Cells. Clinical Chemistry, 2016, 62, 328-334.	1.5	87
185	Liquid biopsy: Potential and challenges. Molecular Oncology, 2016, 10, 371-373.	2.1	67
186	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discovery, 2016, 6, 479-491.	7.7	1,087
187	Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas. Clinical Chemistry, 2016, 62, 378-386.	1.5	29
188	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research, 2016, 22, 2583-2593.	3.2	289
189	Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.. Journal of Clinical Oncology, 2016, 34, 11505-11505.	0.8	1
190	Circulating tumor cells (CTC) and HER-2 status on CTC and primary tumor in urothelial cancer (UC) patients refractory to platinum based chemotherapy.. Journal of Clinical Oncology, 2016, 34, 4520-4520.	0.8	2
191	The DETECT study concept: Individualized therapy of metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS634-TPS634.	0.8	6
192	Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection. PLoS Medicine, 2016, 13, e1002205.	3.9	49
193	Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearchÂ® System and the AdnaTestÂ®. PLoS ONE, 2016, 11, e0155126.	1.1	54
194	RHAMM splice variants confer radiosensitivity in human breast cancer cell lines. Oncotarget, 2016, 7, 21428-21440.	0.8	18
195	Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget, 2016, 7, 34930-34941.	0.8	71
196	Liquid biopsies for surveillance and monitoring treatment response of bladder cancer. Annals of Translational Medicine, 2016, 4, 379-379.	0.7	2
197	Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer.. Journal of Clinical Oncology, 2016, 34, 11529-11529.	0.8	0
198	Heterogeneity of miR-10b expression in circulating tumor cells. Scientific Reports, 2015, 5, 15980.	1.6	33

#	Article	IF	Citations
199	Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells. BMC Cancer, 2015, 15, 896.	1.1	18
200	Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer. Annals of Surgery, 2015, 261, 1124-1130.	2.1	82
201	Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget, 2015, 6, 6341-6358.	0.8	28
202	Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2015, 5, 207.	1.3	56
203	Aberrant plasma levels of circulatingmiR-16, miR-107, miR-130aandmiR-146aare associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget, 2015, 6, 13387-13401.	0.8	88
204	Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. Cancer Research, 2015, 75, 892-901.	0.4	321
205	Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acidâ€“Induced 2. Cancer Discovery, 2015, 5, 506-519.	7.7	45
206	Frequent expression of PDâ€Ł1 on circulating breast cancer cells. Molecular Oncology, 2015, 9, 1773-1782.	2.1	303
207	Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells. BMC Cancer, 2015, 15, 178.	1.1	10
208	The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer, 2015, 15, 403.	1.1	70
209	Data Normalization Strategies for MicroRNA Quantification. Clinical Chemistry, 2015, 61, 1333-1342.	1.5	384
210	Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. British Journal of Cancer, 2015, 113, 1358-1366.	2.9	110
211	Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells. Methods in Molecular Biology, 2015, 1347, 221-232.	0.4	10
212	Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. Expert Review of Molecular Diagnostics, 2015, 15, 1411-1417.	1.5	43
213	Tumour exosome integrins determine organotropic metastasis. Nature, 2015, 527, 329-335.	13.7	3,688
214	Circulating DNA as biomarker in breast cancer. Breast Cancer Research, 2015, 17, 136.	2.2	89
215	Mutant p53 promotes epithelialâ€mesenchymal plasticity and enhances metastasis in mammary carcinomas of <scp>WAPâ€T</scp> mice. International Journal of Cancer, 2015, 136, E521-33.	2.3	17
216	Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response. Cancer Research, 2015, 75, 5367-5377.	0.4	70

#	Article	IF	Citations
217	Evaluation of the germline single nucleotide polymorphism rs583522 in the TNFAIP3 gene as a prognostic marker in esophageal cancer. Cancer Genetics, 2015, 208, 595-601.	0.2	7
218	Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. Cancer Cell, 2015, 28, 552-554.	7.7	132
219	Biology, detection, and clinical implications of circulating tumor cells. EMBO Molecular Medicine, 2015, 7, 1-11.	3.3	453
220	Cell lines from circulating tumor cells. Oncoscience, 2015, 2, 815-816.	0.9	27
221	Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. Oncotarget, 2015, 6, 26789-26803.	0.8	18
222	Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget, 2014, 5, 9650-9663.	0.8	304
223	An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer. Journal of Human Genetics, 2014, 59, 661-666.	1.1	4
224	Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. Journal of the National Cancer Institute, 2014, 106, .	3.0	493
225	Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. International Journal of Cancer, 2014, 135, 1978-1982.	2.3	87
226	Prognostic Relevance of Viable Circulating Tumor Cells Detected by EPISPOT in Metastatic Breast Cancer Patients. Clinical Chemistry, 2014, 60, 214-221.	1.5	102
227	Hematogenous dissemination of glioblastoma multiforme. Science Translational Medicine, 2014, 6, 247ra101.	5.8	264
228	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2014, 15, 406-414.	5.1	703
229	Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Research and Treatment, 2014, 146, 163-174.	1.1	142
230	Tumor signatures in the blood. Nature Biotechnology, 2014, 32, 441-443.	9.4	96
231	Technologies for detection of circulating tumor cells: facts and vision. Lab on A Chip, 2014, 14, 57-62.	3.1	226
232	Clinical relevance of circulating cell-free microRNAs in cancer. Nature Reviews Clinical Oncology, 2014, 11, 145-156.	12.5	915
233	Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. BoneKEy Reports, 2014, 3, 584.	2.7	82
234	Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity. Clinical Cancer Research, 2014, 20, 425-433.	3.2	118

#	Article	IF	Citations
235	Challenges in circulating tumour cell research. Nature Reviews Cancer, 2014, 14, 623-631.	12.8	1,102
236	Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer, 2014, 14, 512.	1.1	65
237	PGC-1Î± mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promoteÂmetastasis. Nature Cell Biology, 2014, 16, 992-1003.	4.6	1,073
238	AKT3 regulates ErbB2, ErbB3 and estrogen receptor Î± expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice. Cellular Signalling, 2014, 26, 1021-1029.	1.7	37
239	Squamous cell carcinoma of the oral cavity and circulating tumour cells. World Journal of Clinical Oncology, 2014, 5, 114.	0.9	35
240	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. Blood, 2014, 124, 4512-4512.	0.6	1
241	Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Medicine, 2013, 5, 30.	3.6	306
242	Tracking tumor resistance using 'liquid biopsies'. Nature Medicine, 2013, 19, 676-677.	15.2	34
243	Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?. Cancer Research, 2013, 73, 6384-6388.	0.4	376
244	Tumor metastasis: moving new biological insights into the clinic. Nature Medicine, 2013, 19, 1450-1464.	15.2	685
245	Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis. Cancer Cell, 2013, 24, 542-556.	7.7	251
246	Circulating Tumor Cells: Liquid Biopsy of Cancer. Clinical Chemistry, 2013, 59, 110-118.	1.5	942
247	Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer. Clinical Chemistry, 2013, 59, 252-260.	1.5	215
248	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 137, 503-510.	1.1	118
249	Frequent Genetic Alterations in EGFR- and HER2-Driven Pathways in Breast Cancer Brain Metastases. American Journal of Pathology, 2013, 183, 83-95.	1.9	63
250	Biologic Challenges in the Detection of Circulating Tumor Cells. Cancer Research, 2013, 73, 8-11.	0.4	199
251	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 2013, 31, 539-544.	9.4	920
252	Tumor Cell Dissemination: Emerging Biological Insights from Animal Models and Cancer Patients. Cancer Cell, 2013, 23, 573-581.	7.7	365

#	Article	IF	Citations
253	Lowâ€grade and highâ€grade mammary carcinomas in WAPâ€T transgenic mice are independent entities distinguished by Met expression. International Journal of Cancer, 2013, 132, 1300-1310.	2.3	15
254	Capture of Viable Circulating Tumor Cells in the Liver of Colorectal Cancer Patients. Clinical Chemistry, 2013, 59, 1384-1392.	1.5	182
255	Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing. Cancer Research, 2013, 73, 2965-2975.	0.4	497
256	Plastin3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelialâ€“Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis. Cancer Research, 2013, 73, 2059-2069.	0.4	220
257	Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer. Journal of Biological Chemistry, 2013, 288, 22993-23008.	1.6	103
258	Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study.. Journal of Clinical Oncology, 2013, 31, 11042-11042.	0.8	1
259	Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients. PLoS ONE, 2013, 8, e75038.	1.1	114
260	Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC).. Journal of Clinical Oncology, 2013, 31, e22075-e22075.	0.8	0
261	Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. Blood, 2013, 122, 1469-1469.	0.6	0
262	Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells. Clinical Cancer Research, 2012, 18, 993-1003.	3.2	130
263	Circulating Epithelial Cells in Patients with Benign Colon Diseases. Clinical Chemistry, 2012, 58, 936-940.	1.5	229
264	Disseminated Tumor Cells in Bone Marrow and the Natural Course of Resected Esophageal Cancer. Annals of Surgery, 2012, 255, 1105-1112.	2.1	39
265	Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Research, 2012, 14, R49.	2.2	93
266	Prognostic impact of circulating tumor cells assessed with the CellSearch Systemâ„¢ and AdnaTest Breastâ„¢ in metastatic breast cancer patients: the DETECT study. Breast Cancer Research, 2012, 14, R118.	2.2	160
267	Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer and Metastasis Reviews, 2012, 31, 673-687.	2.7	192
268	Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer. Clinical Cancer Research, 2012, 18, 5701-5710.	3.2	330
269	Considerations in the development of circulating tumor cell technology for clinical use. Journal of Translational Medicine, 2012, 10, 138.	1.8	282
270	ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. International Journal of Cancer, 2012, 131, 396-405.	2.3	40

#	Article	IF	Citations
271	Disseminated tumor cells in pancreatic cancerâ€"an independent prognosticator of disease progression and survival. International Journal of Cancer, 2012, 131, E475-83.	2.3	30
272	Highâ€resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. International Journal of Cancer, 2012, 131, E405-15.	2.3	48
273	The Interrelating Dynamics of Hypoxic Tumor Microenvironments and Cancer Cell Phenotypes in Cancer Metastasis. Cancer Microenvironment, 2012, 5, 59-72.	3.1	22
274	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. European Urology, 2012, 61, 810-817.	0.9	163
275	HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial.. Journal of Clinical Oncology, 2012, 30, 10540-10540.	0.8	1
276	Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. Journal of Clinical Oncology, 2012, 30, 1090-1090.	0.8	0
277	Clinical relevance and biology of circulating tumor cells. Breast Cancer Research, 2011, 13, 228.	2.2	126
278	Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer, 2011, 11, 426-437.	12.8	2,372
279	VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging Î±4Î²1-Positive Osteoclast Progenitors. Cancer Cell, 2011, 20, 701-714.	7.7	445
280	Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cellular Signalling, 2011, 23, 1952-1960.	1.7	76
281	Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Research and Treatment, 2011, 125, 729-738.	1.1	33
282	Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapseâ€"A European Pooled Analysis. Clinical Cancer Research, 2011, 17, 2967-2976.	3.2	244
283	Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia. Blood, 2011, 118, 940-940.	0.6	0
284	Discovery of a Novel Unfolded Protein Response Phenotype of Cancer Stem/Progenitor Cells from the Bone Marrow of Breast Cancer Patients. Journal of Proteome Research, 2010, 9, 3158-3168.	1.8	89
285	HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Research and Treatment, 2010, 124, 403-412.	1.1	330
286	Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Annals of the New York Academy of Sciences, 2010, 1210, 66-77.	1.8	71
287	Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clinical Cancer Research, 2010, 16, 2634-2645.	3.2	463
288	Circulating tumour cells in cancer patients: challenges and perspectives. Trends in Molecular Medicine, 2010, 16, 398-406.	3.5	616

#	Article	IF	Citations
289	Are circulating tumor cells predictive of overall survival?. Nature Reviews Clinical Oncology, 2009, 6, 190-191.	12.5	61
290	Genomic Profiles Associated with Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion. Clinical Cancer Research, 2009, 15, 1566-1574.	3.2	87
291	Cancer micrometastases. Nature Reviews Clinical Oncology, 2009, 6, 339-351.	12.5	625
292	Two-Dimensional Differential Gel Electrophoresis of a Cell Line Derived from a Breast Cancer Micrometastasis Revealed a Stem/Progenitor Cell Protein Profile. Journal of Proteome Research, 2009, 8, 2004-2014.	1.8	48
293	Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Research, 2009, 11, R39.	2.2	146
294	Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer. Clinical Cancer Research, 2009, 15, 1032-1038.	3.2	221
295	Clinical Relevance of Disseminated Tumor Cells in the Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients. Breast Care, 2009, 4, 333-338.	0.8	8
296	Review: Biological relevance of disseminated tumor cells in cancer patients. International Journal of Cancer, 2008, 123, 1991-2006.	2.3	309
297	Detection and Monitoring of Cellâ€Free DNA in Blood of Patients with Colorectal Cancer. Annals of the New York Academy of Sciences, 2008, 1137, 190-196.	1.8	158
298	Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews Cancer, 2008, 8, 329-340.	12.8	1,037
299	Prognostic Significance of Disseminated Tumor Cells in the Bone Marrow of Prostate Cancer Patients Treated With Neoadjuvant Hormone Treatment. Journal of Clinical Oncology, 2008, 26, 4928-4933.	0.8	83
300	Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System. Clinical Cancer Research, 2007, 13, 920-928.	3.2	1,204
301	Detection and Characterization of Putative Metastatic Precursor Cells in Cancer Patients. Clinical Chemistry, 2007, 53, 537-539.	1.5	182
302	A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer, 2006, 107, 885-892.	2.0	211
303	Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. Journal of Surgical Oncology, 2006, 94, 307-315.	0.8	29
304	Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors.. Blood, 2006, 108, 3947-3947.	0.6	0
305	Tumor-Cell Homing to Lymph Nodes and Bone Marrow and CXCR4 Expression in Esophageal Cancer. Journal of the National Cancer Institute, 2005, 97, 1840-1847.	3.0	199
306	Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity. Clinical Cancer Research, 2005, 11, 3678-3685.	3.2	372

#	Article	IF	Citations
307	A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer. New England Journal of Medicine, 2005, 353, 793-802.	13.9	1,274
308	Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells. Clinical Cancer Research, 2005, 11, 8006-8014.	3.2	277
309	Dissecting the metastatic cascade. Nature Reviews Cancer, 2004, 4, 448-456.	12.8	1,194
310	Occult Tumor Cells in Bone Marrow of Patients With Locoregionally Restricted Ovarian Cancer Predict Early Distant Metastatic Relapse. Journal of Clinical Oncology, 2001, 19, 368-375.	0.8	72
311	Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients. Journal of Clinical Oncology, 2000, 18, 80-80.	0.8	367
312	Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancer. New England Journal of Medicine, 2000, 342, 525-533.	13.9	881
313	Prognostic Value of Immunohistochemically Identifiable Tumor Cells in Lymph Nodes of Patients with Completely Resected Esophageal Cancer. New England Journal of Medicine, 1997, 337, 1188-1194.	13.9	347
314	Methodological Analysis of Immunocytochemical Screening for Disseminated Epithelial Tumor Cells in Bone Marrow. Stem Cells and Development, 1994, 3, 165-173.	1.0	263